Elixir Medical Announces First Patient Treated in Bioadaptor Randomized Controlled Trial of DynamX Coronary Bioadaptor System
International Trial to Compare Bioadaptor, a Novel Coronary Artery Implant Designed to Adapt to Vessel Physiology, with Traditional Drug Eluting Stents MILPITAS, Calif. – January 13, 2020 – Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced that the first patient has been treated in the BIOADAPTOR randomized controlled trial (RCT) of the DynamX™ […]
Elixir Medical Announces Outstanding 12-Month Data for DynamX Coronary Bioadaptor System, Demonstrating No Target Vessel Revascularization, No Thrombosis and Positive Adaptive Remodeling of the Artery
PARIS – June 25, 2020 — Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced outstanding 12-month data for the DynamX™ Coronary Bioadaptor System, the first coronary artery implant that adapts to vessel physiology. Results will be presented live tomorrow at 14:12 CEST on the Main Arena channel of the PCR e-Course as part of the […]
Elixir Medical Corporation Announces Outstanding 5-Year Clinical Data for CE Mark-Approved DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System
Excellent Six-Month Safety and Efficacy Results for Next-Generation Thin-strut DESolve® Cx Novolimus Eluting Bioresorbable Coronary Scaffold System also presented Milpitas, CA – May 17, 2017 — Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, today announced excellent 5-year clinical data from the DESolve Nx international pivotal clinical trial for the CE Mark-approved, […]
Elixir Medical Corporation Unveils Transformational DynamX Stent Featuring Adaptive Segments That Uncage the Stented Artery
Elixir Reveals New Category of ‘Bioadaptive Drug Eluting Stents’ (BA- DES), Sharing DynamX Technology, Preclinical Data, and Clinical Program at 29th Transcatheter Cardiovascular Therapeutics Conference Milpitas, Calif. (October 31, 2017) – Elixir Medical Corporation, a leader in the development of breakthrough adaptive remodeling technologies designed to mimic the normal arterial function after cardiovascular and peripheral […]
Elixir Medical Corporation Announces Excellent Six-Month Safety and Efficacy Results for Thin-Strut DESolve Cx Novolimus Eluting Bioresorbable Coronary Scaffold System
Sunnyvale, CA —October 31, 2016—Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced today that a successful live case demonstration of its next-generation DESolve® NXT Plus Novolimus Eluting Bioresorbable Coronary Scaffold System was presented at the 28th annual Transcatheter Cardiovascular Therapeutics (TCT) meeting in Washington, DC. “This live demonstration presented […]
Successful Live Case Demonstration of Elixir Medical’s Fully Bioresorbable DESolve NXT Plus Novolimus Eluting Coronary Scaffold System at TCT
Sunnyvale, CA —October 31, 2016—Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced today that a successful live case demonstration of its next-generation DESolve® NXT Plus Novolimus Eluting Bioresorbable Coronary Scaffold System was presented at the 28th annual Transcatheter Cardiovascular Therapeutics (TCT) meeting in Washington, DC. “This live demonstration presented […]
Akesys Medical and Elixir Medical Announce First Human Implant of the PRAVA Bioresorbable Scaffold for Peripheral Vascular Disease
Sunnyvale, CA — October 20, 2016 – Akesys Medical, a drug-device company focused on pioneering innovative solutions for peripheral artery disease, has announced their first clinical trial and successful implant of the breakthrough PRAVA™ Sirolimus Eluting Bioresorbable Peripheral Scaffold System for the treatment of blockage in the superficial femoral artery (SFA). The Akesys PRAVA™ scaffold is […]
Elixir Medical Announces Excellent, 3-Year Clinical and Imaging Results for the CE-Marked Fully Bioresorbable DESolve Novolimus Eluting Coronary Scaffold System
Golden Tube Visualization, Low MACE and Lumen Gain Sustained Long-Term Sunnyvale, Calif. – October 15, 2015 — Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced excellent 3-year clinical and imaging results from the DESolve Nx international pivotal clinical trial for the CE Mark-approved, fully bioresorbable DESolve® Novolimus Eluting Coronary Scaffold System. […]
Elixir Medical Announces Successful Live Case Transmission of DESolve Cx at TCT
Sunnyvale, Calif. – October 13, 2015 — Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced that on Mon., October 12, Professor Alexandre Abizaid, M.D., Ph.D., of The Instituto Dante Pazzanese de Cardiologia, Brazil, conducted a successful implantation of its breakthrough and fully bioresorbable DESolve® Cx Novolimus Eluting Coronary Scaffold System that […]
Elixir Medical Receives 2015 Innovator of the Year Award from EK-UNICO
Sunnyvale, Calif. – August 17, 2015 — Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced that it has received the prestigious ‘Innovator of the Year’ for 2015 at the annual conference of EK-UNICO in Germany. With a presence in more than 20 countries, Elixir Medical was selected for this honor […]